NO20042697L - Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist - Google Patents

Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist

Info

Publication number
NO20042697L
NO20042697L NO20042697A NO20042697A NO20042697L NO 20042697 L NO20042697 L NO 20042697L NO 20042697 A NO20042697 A NO 20042697A NO 20042697 A NO20042697 A NO 20042697A NO 20042697 L NO20042697 L NO 20042697L
Authority
NO
Norway
Prior art keywords
antagonist
toll
tumor
methods
combination
Prior art date
Application number
NO20042697A
Other languages
English (en)
Norwegian (no)
Inventor
Alain P Vicari
Christophe Caux
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20042697L publication Critical patent/NO20042697L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20042697A 2001-11-27 2004-06-25 Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist NO20042697L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33343401P 2001-11-27 2001-11-27
PCT/US2002/038098 WO2003045431A2 (en) 2001-11-27 2002-11-26 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist

Publications (1)

Publication Number Publication Date
NO20042697L true NO20042697L (no) 2004-06-25

Family

ID=23302758

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042697A NO20042697L (no) 2001-11-27 2004-06-25 Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist

Country Status (14)

Country Link
US (2) US20030138413A1 (xx)
EP (1) EP1450858A2 (xx)
JP (3) JP2006502080A (xx)
CN (1) CN1617742B (xx)
AU (1) AU2002359516B2 (xx)
BR (1) BR0214457A (xx)
CA (1) CA2468320A1 (xx)
HU (1) HUP0500999A2 (xx)
MX (1) MXPA04004998A (xx)
NO (1) NO20042697L (xx)
NZ (1) NZ565420A (xx)
TW (1) TW200303759A (xx)
WO (1) WO2003045431A2 (xx)
ZA (1) ZA200404113B (xx)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) * 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1311288A1 (en) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
US20040175355A1 (en) * 2001-04-18 2004-09-09 The Regents Of The University Of California Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
US7387271B2 (en) * 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
WO2004074437A2 (en) * 2003-02-14 2004-09-02 University Of Southern California Compositions and methods for cancer immunotherapy
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US20060182793A1 (en) * 2003-07-22 2006-08-17 Cytos Biotechnology Ag Cpg-packaged liposomes
CA2552750C (en) * 2004-01-07 2021-11-09 Chiron Corporation M-csf-specific monoclonal antibody and uses thereof
TW200533750A (en) * 2004-02-19 2005-10-16 Coley Pharm Group Inc Immunostimulatory viral RNA oligonucleotides
JP2008522951A (ja) * 2004-07-19 2008-07-03 ベイラー・カレツジ・オブ・メデイシン サイトカインシグナル伝達調節物質の調節および免疫療法のための応用
CN101018567B (zh) * 2004-07-20 2011-07-27 先灵公司 表达Toll样受体的肿瘤细胞凋亡的诱导
WO2007050095A2 (en) 2004-11-19 2007-05-03 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US20080166369A1 (en) * 2004-12-28 2008-07-10 Immuno Frontier, Inc. Cancer Vaccine Preparation
EP1712241A1 (en) * 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
CN101501055B (zh) * 2005-06-23 2016-05-11 贝勒医学院 负性免疫调节因子的调节和免疫疗法应用
MX2008000596A (es) * 2005-07-11 2008-03-19 Cbio Ltd Inmunomodulacion inducida por la chaperonina 10.
GB2448255A (en) * 2005-12-01 2008-10-08 Trinity College Dublin Compositions and methods relating to treatment of cancer and infectious diseases
NZ569741A (en) 2005-12-14 2012-02-24 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
SI2032592T1 (sl) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Postopki za pakiranje oligonukleotidov v virusu-podobne delce RNA bakteriofagov
DE102006035618A1 (de) * 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
CN101610671A (zh) * 2006-12-12 2009-12-23 艾德拉药物股份有限公司 合成的tlr9激动剂
US8445442B2 (en) * 2007-04-26 2013-05-21 University Of Vermont And State Agricultural College CCL18 and CCL3 methods and compositions for detecting and treating cancer
JP2011505144A (ja) * 2007-11-30 2011-02-24 ベイラー カレッジ オブ メディシン 樹状細胞ワクチン組成物およびその使用
AU2010208250A1 (en) * 2009-01-30 2011-08-04 Idera Pharmaceuticals, Inc. Synthetic agonists of TLR 9
MX346912B (es) 2009-12-07 2017-04-05 Univ Leland Stanford Junior Metodos para mejorar terapia con anticuerpos antitumor.
US20120309691A1 (en) * 2010-02-04 2012-12-06 Dapeng Zhou Tumor targeted delivery of immunomodulators by nanopolymers
US20130108661A1 (en) 2010-02-05 2013-05-02 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
WO2012011100A1 (en) 2010-07-19 2012-01-26 Yeda Research And Development Co. Ltd. Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases
US20120039916A1 (en) * 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
CA2876150A1 (en) * 2012-06-08 2013-12-12 The Johns Hopkins University Compostions and methods for cancer immunotherapy
WO2014004809A2 (en) * 2012-06-27 2014-01-03 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10
CN104603156B (zh) 2012-09-05 2016-10-26 中外制药株式会社 引入有氨基酸和甾基的透明质酸衍生物
CN103768604B (zh) * 2012-10-24 2016-03-30 北京圣沃德生物科技有限公司 治疗性肿瘤疫苗
SG10201704611WA (en) 2012-12-13 2017-07-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
CN103013915B (zh) * 2013-01-09 2014-05-28 高岱清 一种高活性负载抗原的树突状细胞的制备方法
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
PL2996473T3 (pl) 2013-05-18 2020-06-01 Aduro Biotech, Inc. Kompozycje i sposoby aktywacji sygnałowania zależnego od „stymulatora genu interferonu”
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
EP3508198A1 (en) 2014-06-04 2019-07-10 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
ES2753259T3 (es) 2015-04-22 2020-04-07 Curevac Ag Composición que contiene ARN para el tratamiento de enfermedades tumorales
US20180127717A1 (en) * 2015-05-07 2018-05-10 Baylor College Of Medicine Dendritic cell immunotherapy
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
AU2016270782B2 (en) * 2015-05-29 2021-08-12 Dynavax Technologies Corporation Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
US20180161427A1 (en) * 2015-05-29 2018-06-14 Merck Sharp & Dohme Corp. Combination of an anti-il-10 antibody and a cpg-c type oligonucleotide for treating cancer
EP3331612A4 (en) * 2015-08-06 2019-07-03 Memorial Sloan Kettering Cancer Center METHOD AND COMPOSITIONS FOR TUMOR THERAPY
TW201716084A (zh) * 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
WO2017192470A1 (en) * 2016-05-03 2017-11-09 Merck Sharp & Dohme Corp. Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018060514A1 (en) 2016-09-30 2018-04-05 Galderma Research & Development Methods and compositions combining at least one pattern recognition receptor (prr) agonist with an anti-il10 receptor antibody
WO2018060513A1 (en) 2016-09-30 2018-04-05 Galderma Research & Development Methods and compositions for treating precancerous lesions or cancer comprising tlr/tlr or tlr/clr agonists
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
IL268744B2 (en) * 2017-02-17 2024-08-01 Aivita Biomedical Inc Methods for increasing the immunogenicity of tumors and preparations for autologous immunotherapeutic products against cancer using tumor cells and adapted dendritic cells
WO2018225062A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
AU2019288277A1 (en) * 2018-06-19 2021-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand
JP2023514727A (ja) 2020-02-21 2023-04-07 シルバーバック セラピューティックス インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
EP4175673A1 (en) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Anti-asgr1 antibody conjugates and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63503308A (ja) * 1986-05-09 1988-12-02 スローン‐ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ 抗腫瘍療法のためのリポ多糖体及び天然因子の組成物及び治療方法
AU685074B2 (en) * 1992-12-14 1998-01-15 Start Technology Partnership Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of neurological pathologies
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ATE420171T1 (de) * 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
EP0930893B1 (en) * 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
DE69935507T2 (de) * 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
IL145982A0 (en) * 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
EP1261366A4 (en) * 2000-02-24 2003-06-18 Univ Leland Stanford Junior ADJUVANT TREATMENT BY ACTIVATING DENDRITIC CELLS IN VIVO
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma

Also Published As

Publication number Publication date
AU2002359516A1 (en) 2003-06-10
JP2006131638A (ja) 2006-05-25
HUP0500999A2 (en) 2007-11-28
NZ565420A (en) 2009-09-25
MXPA04004998A (es) 2005-04-08
WO2003045431A3 (en) 2004-01-22
CN1617742B (zh) 2010-10-27
AU2002359516B2 (en) 2006-02-02
ZA200404113B (en) 2006-03-29
JP2006502080A (ja) 2006-01-19
CN1617742A (zh) 2005-05-18
BR0214457A (pt) 2006-11-21
JP2010053140A (ja) 2010-03-11
WO2003045431A2 (en) 2003-06-05
CA2468320A1 (en) 2003-06-05
TW200303759A (en) 2003-09-16
EP1450858A2 (en) 2004-09-01
US20030138413A1 (en) 2003-07-24
US20090087440A1 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
NO20042697L (no) Fremgangsmater for behandling av kreft ved anvendelse av en kombinasjon av en tumoravledet dendrittcelleinhiberende faktor-antagonist og en Toll-lignende reseptorantagonist
IL166625A0 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
HK1103654A1 (en) A method of treating cancer comprising a vegf-b antagonist b(vegf-b)
NO20033995L (no) Fremgangsmate ved frakturering av en underjordisk formasjon
DE60040956D1 (de) Riss- und splitterbeständiger Bohrlochzement
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DK3342411T3 (da) Rapamycinderivat til behandling af pancreascancer
DK1360287T3 (da) Fremgangsmåder til modifikation af eukaryotiske celler
PL363339A1 (en) Method of checking ballast profile
PL371492A1 (en) Quinolinone derivatives for treating cell proliferation related disorders
NO20031489D0 (no) Fremgangsmåte og anordning ved trekkbar broplugg
NO20033684L (no) Behandling av refrakt¶re tumorer ved anvendelse av epotilonderivater
NO20033429D0 (no) Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK)
EP1425399A4 (en) COMBINATIVE METHODS FOR CELL DOD INDUCTION IN CANCER CELLS
NO20032966D0 (no) Fremgangsmåte og anordning ved utboring av sementplugger
AU2002317105A1 (en) Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
EP1436423A4 (en) GENETIC ANALYSIS TO STRATIFY CANCER RISK
AU2002308522A8 (en) Methods for inhibiting tumor cell proliferation
EP1549938A4 (en) IDENTIFICATION OF BIOMARKERS TO DETECT PROSTATE CANCER
DK1046462T3 (da) Waferholdeplade til waferslibeapparat og fremgangsmåde til fremstilling af denne
NO20015242L (no) Fremgangsmåte for påvisning og dreping av epiteliale kreftceller
EP1401377A4 (en) CANCER TREATMENT METHODS
EP1569516A4 (en) METHOD OF INHIBITING CANCER AND TARGET EDUCATION
GB0201504D0 (en) Method of payment
IS7438A (is) Lyfjablanda úr PDE4 eða PDE3/4 tálma og histamínviðtakamótlyfi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application